AMY E. HERR, John D. and Catherine T. MacArthur Professor, University of California, Berkeley, Berkeley, CA, USA
Plenary Lecture on "Electrophoretic Cytometry: Single-cell and Sub-cellular Targeted Proteomics using Microfluidic Design"
Amy E. Herr, Ph.D. is the MacArthur Professor at UC Berkeley, where she directs a bioengineering research group that addresses unmet measurement needs spanning fundamental life sciences (developmental biology) to clinical practice (oncology). At the interface of microsystems design, analytical chemistry, and protein science, her group designs precision microsystems to study biology, with a focus on targeted proteomic tools offering single-cell and subcellular resolution. Her research advances the "mathematization" of biology and medicine. She was a staff scientist at Sandia National Laboratories. She is an elected fellow of the National Academy of Inventors and the American Institute of Medical and Biological Engineering, is an NIH New Innovator, NSF CAREER awardee, Sloan Research Fellow, Ellen Weaver Awardee (AWIS) for mentoring, 2019 Faculty Award for Excellence in Postdoctoral Mentoring from UC Berkeley, and a City of Berkeley Visionary Awardee, among others. She sits on the NIH’s National Advisory Council for Bioengineering, the DARPA Biological Insights Board, and is part of the US Air Force’s Science Advisory Board. She has chaired the premiere conferences in her field (Gordon Research Conference, 2009; microTAS, 2021), directs the Bakar Fellows Program and the Bakar BioEnginuity Hub (opening 2022), and is a successful entrepreneur.
BARRY L. KARGER, James L. Waters Emeritus Chair and Distinguished Professor, Barnett Institute Emeritus Director, Northeastern University, Boston, MA USA
Founder's Lecture on "Microscale Bioseparations and Analysis : A Look Into the Past and the Future"
Barry L. Karger is the Emeritus James L. Waters Chair in Analytical Chemistry and Distinguished Professor at Northeastern University. He was the Founding and now Emeritus Director of the Barnett Institute of Chemical and Biological Analysis. In 1989, he was the Founding Chairman of the HPCE meeting, the forerunner of the present MSB series. Dr. Karger has been an active researcher with over 375 publications and 50 patents in the field of bioanalytical chemistry. He has been a major contributor to the development of HPLC, and his technology in capillary electrophoresis played a significant role in the Human Genome Project. More recently, he was involved in the development of new technologies for proteomics, especially trace level LC/MS analysis of proteins in biological matrices, and comprehensive characterization of complex biopharmaceuticals. He has co-founded several companies and actively collaborated with others in the biotechnology industry. Over 125 Ph.D. students, postdocs and staff scientists have gone onto distinguished careers from his laboratory. Dr. Karger has received many honors including three American Chemical Society awards, the Bergman Medal from the Swedish Chemical Society, the Herovsky Gold Medal from the Czech Academy of Sciences, and the Beckman Medal.
LUKE P. LEE, Professor, Harvard Medical School, Department of Medicine, Brigham Women’s Hospital, Boston, MA, USA
Plenary Lecture on "Organoids Microphysiological Analysis Platforms (MAP) and Exosome Detection via the Ultrafast-isolation System (EXODUS)"
Prof. Luke P. Lee received both his BA in Biophysics and PhD in Applied Physics and Bioengineering from UC Berkeley. He joined the faculty at the UC Berkeley in 1999 after more than a decade of industry experience. He became the Lester John and Lynne Dewar Lloyd Distinguished Professor of Bioengineering in 2005. He also served as the Chair Professor in Systems Nanobiology at the ETH Zürich from 2006 to 2007. He became Arnold and Barbara Silverman Distinguished Professor at Berkeley in 2010. He founded the Biomedical Institute for Global Healthcare Research & Technology (BIGHEART) at the National University of Singapore. He is the founding director of Institute for Quantum Biophysics, Sungkyunkwan University, Korea. He is a Fellow of the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering. His work at the interface of biological, physical, and engineering sciences for medicine has been recognized by many honors including the IEEE William J. Morlock Award, NSF Career Award, Fulbright Scholar Award, and the HoAm Prize. Lee has over 350 peer-reviewed publications and over 60 international patents filed. His current research interests are exosome, organoids MAP, early detection of infectious diseases, cancer, and neurodegenerative diseases.
MATTHIAS MANN, Professor, Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Munich, GERMANY and Director of Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, DENMARK
Plenary Lecture on "Robust and In-depth Work Flows for Single Cell and Clinical Proteomics"
Matthias Mann studied physics and mathematics at Göttingen University in Germany and obtained his Ph.D. in chemical engineering at Yale where his work contributed to the Nobel Prize for his supervisor John Fenn in 2012 for the development of electrospray ionization. Thereafter at the University of Southern Denmark he developed the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a paradigm-shifting method of quantitative proteomics and a breakthrough in the mapping of protein interactions. In 2005 Matthias Mann was appointed head of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry, Martinsried near Munich and since 2009 has an additional appointment as director of the Department of Proteomics, Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. His work has been decisive in making mass spectrometry applicable to molecular biology. He has developed computer algorithms to match mass spectrometric data with sequence databases and introduced methods for accurate quantitation into proteomics and downstream biology. His team works in proteomics technology development and performs global large-scale proteomic and phosphoproteomic studies in different biological questions and medical fields. The Mann laboratory is a technical leader in the field of mass spectrometry and has pushed the technology ever-deeper coverage of proteomes for over two decades. The group increasingly focusses on clinically relevant topics, especially the analysis of the blood plasma proteome. The establishment of a robust and reproducible high-throughput proteome profiling pipeline for the analysis of whole blood, plasma and serum samples will soon allow the proteomic screening of clinical cohorts for new biomarkers or biomarker patterns. He has been elected as a member of EMBO, the Royal Danish Academy of Arts and Sciences and the Leopoldina German National Academy of Sciences. In 2012 he was awarded the Leibniz Prize from the German Research Foundation, the Ernst Schering Prize, the Louis-Jeantet Foundation Prize for Medicine and the Körber European Science Prize. In 2015 was awarded the Barry L. Karger Medal in Bioanalytical Chemistry and the Theodor Bücher Lecture and Medal as well as the Danish Order of Dannebrog Knights Cross and in 2019 was nominated as a member of the Bavarian Academy of Sciences and Humanities. He holds two honorary doctorates. He is author of over 700 publications and one of the most cited scientists worldwide with an h-factor of 237 and more than 260,000 total citations (Google Scholar).
Recipient of the Thermo Fisher Scientific Early Career Award 2021:
LIANGLIANG SUN, Assistant Professor, Department of Chemistry, Michigan State University, East Lansing, MI, USA
Presentation title: "Leveraging Capillary Electrophoresis-Mass Spectrometry for Multi-level Proteomics"
Dr. Liangliang Sun is an Assistant Professor in the Department of Chemistry at Michigan State University. He joined MSU in 2016. Before that, he worked with Prof. Norman Dovichi at University of Notre Dame as a postdoctoral fellow and later a Research Assistant Professor (2011-2016). He received his Ph.D. degree in Analytical Chemistry in 2011 from Dalian Institute of Chemical Physics, Chinese Academy of Sciences, advised by Profs. Yukui Zhang and Lihua Zhang. The Sun group aims to develop novel analytical methodologies based on capillary electrophoresis-tandem mass spectrometry (CE-MS/MS) for multi-level proteomics to characterize proteins (bottom-up proteomics), proteoforms (top-down proteomics), and protein complexes (native proteomics) in cells globally with high throughput, high sensitivity, and single-cell resolution. They deploy the multi-level proteomics to address important questions in developmental biology and cancer biology. He has published 100 peer-reviewed papers, which have accumulated 2300 citations (h-index: 30. Web of Science). His research group at Michigan State University has published 25 papers in the last four years. He has been recognized as an Emerging Investigator by the Journal of the American Society for Mass Spectrometry and Analytical Methods. He received the National Science Foundation CAREER AWARD in 2019.
MEHMET TONER, Helen Andrus Benedict Professor of Biomedical Engineering, Co-Director, Center for Engineering in Medicine & Surgery, Massachusetts General Hospital & Harvard Medical School, Harvard-MIT Health Sciences & Technology, Boston, MA, USA
Plenary Lecture on "Microfluidic Sorting of Extremely Rare Circulating Tumor Cells and Clusters from Blood"
Dr. Toner holds the Helen Andrus Benedict Professor of Biomedical Engineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Division of Health Sciences and Technology. He serves as the Director of Research at the Shriners Hospitals for Children in Boston, and the Co-Director of the Center for Engineering in Medicine and Surgery. Dr. Toner received BS degree from Istanbul Technical University and MS degree from the Massachusetts Institute of Technology (MIT), both in Mechanical Engineering. Subsequently he completed his PhD degree in Medical Engineering at Harvard-MIT Division of Health Sciences and Technology in 1989. Dr. Toner published more than 350 original articles and has delivered 400+ presentations. His research involves microfluidics, nano- and micro-technologies, tissue engineering and regenerative medicine, cryobiology. Dr. Toner is also co-founder of multiple biotechnology and medical device start-ups. Dr. Toner is a Fellow of “the American Institute of Medical and Biological Engineering”; “the American Society of Mechanical Engineers”, and “the Society for Cryobiology.” He received several awards from the American Society of Mechanical Engineers including “YC Fung Young Scientist Award” (1994), “H.R. Lissner Medal” (2013), “Savio-Woo Medal” (2020). In 2012, he was given the “Luyet Medal” by the Society for Cryobiology. He is also a member of the US National Academy of Inventors, US National Academy of Engineering, and the US National Academy of Medicine.
GREGORY VERDINE, President, Chief Executive Officer, FogPharma, Cambridge, MA, USA
Plenary Lecture on "Toward Universal Druggability"
Dr. Greg Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Dr. Verdine coined the phrase “drugging the undruggable” to describe his life’s mission. FogPharma was born from the new modality scientific work of Dr. Verdine. Together with co-founder WeiQing Zhou, he developed the scientific and business concept for the company and co-led its capitalization and operationalization in mid-2016. Dr. Verdine held the role of Chairman of the Board from company founding until December 2020. Dr. Verdine is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving Professor at Harvard University and Harvard Medical School, he invented stapled peptides, including the precursor to the Phase II molecule ALRN 6924, and also made seminal contributions to understanding fundamental mechanisms of DNA repair and epigenetic DNA methylation. As an entrepreneur, Dr. Verdine has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Dr. Verdine has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and LifeMine Therapeutics. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and LifeMine, Dr. Verdine took a role in managing these companies as their president, chief executive officer and chief scientific officer. Dr. Verdine earned his Ph.D. in chemistry from Columbia University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.
The recipient of the SCIEX Innovation Award 2021:
PETER WILLIS, Group Supervisor, Chemical Analysis & Life Detection, NASA Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
Presentation title: "Biosignatures, Electrophoresis, and the Search for Life Beyond Earth"
Peter Willis received his doctorate in chemistry from Cornell University, after designing and building a one-ton crossed molecular beams machine that he used to probe the fundamental nature of interactions between metal atoms and organic molecules. He continued his studies through postdoctoral fellowships at Rice University and Caltech, where he expanded his scientific horizons beyond spectroscopy and chemical reaction dynamics, and into the fields of carbon nanotechnology, molecular computing, systems biology, and biosensing. In recognition of his pioneering work on carbon fullerenes with Nobel Laureate Richard Smalley, on January 1st, 2000 he was highlighted by Maclean’s magazine as one of the “100 Canadians to Watch in the New Millennium”. Two years later, drawn by the inescapable pull of the search for life beyond Earth, he joined the technical staff of NASA’s Jet Propulsion Laboratory. Dr. Willis is currently the Group Supervisor of JPL’s Chemical Analysis and Life Detection group. His research focuses on invention of new methods and technologies capable of identifying and characterizing signatures of extraterrestrial life at the molecular level. Portable instrument systems developed in his group are validated in a variety of harsh terrestrial environments that range from high deserts and hypersaline lakes, to oceans and icy polar regions. The ultimate goal is to incorporate this technology into the payloads of robotic explorers bound for the ocean worlds of our outer solar system. To that end he has played a key role in the formulation of a variety of mission concepts to explore Titan, Enceladus, and Europa. In 2017 he co-authored the “Europa Lander Mission Science Definition Team Report”, a publication which broadly serves as a guide to life detection for all future planetary missions in our solar system. In addition to laying the foundation for these missions of the coming decades, Dr. Willis also currently serves as staff scientist for the ongoing Perseverance Mars rover mission. His primary focus is on the use of chemical and mineralogical analysis to enable the selection of the most astrobiologically promising samples for potential return to Earth for analysis in terrestrial laboratories. And finally, Dr. Willis also has a strong commitment to academics, serving as Adjunct Professor in the Department of Chemistry at University of Kansas. He is a frequent reviewer for a wide range of chemistry-related scientific journals and has mentored over 40 individuals at the undergraduate, graduate, and postdoctoral levels during the course of his research.
JOHN YATES, Ernest W. Hahn Professor, Departments of Molecular Medicine and Neurobiology, The Scripps Research Institute, La Jolla, CA, USA
Plenary Lecture on "Proteomics 3.0: “Space” the New Frontier"
John R. Yates is the Ernest W. Hahn Professor in the Departments of Molecular Medicine and Neurobiology at Scripps Research. His research interests include development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data, and biological studies involving proteomics. He is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for the analysis of protein mixtures. His laboratory has developed proteomic techniques to analyze protein complexes, posttranslational modifications, organelles and quantitative analysis of protein expression for the study of biology. He has received awards including the ASMS Biemann Medal, HUPO Achievement Award, Christian Anfinsen Award (Protein Society), Analytical Chemistry award (ACS), Ralph N. Adams Award, Thomson Medal (IMSF), John B. Fenn Award (ASMS), HUPO Discovery Award. He is currently the EIC at the Journal of Proteome Research.